The Digital Therapeutics Alliance has released an updated guide to the International DTx Regulatory & Reimbursement Pathways for 8 major markets, including the US (which desperately needs to accelerate coverage and adoption of innovative treatments in areas of unmet need).
read full article ›Thank you to all of the donors who have helped keep the nation's blood supply ready when needed. Learn more about how you are helping your community at www.bloodcenter.org!
read full article ›The write-ups of the Illumina JPM talk, all highlighting progress with coverage of oncology testing, missed one crucial point: the big research deal with a new United/Optum unit (Optum Evidence Engine). In Dx — given next-gen and WG sequencing VBA deals with Harvard Pilgrim Health Care (Point32Health) — Illumina clearly seems to be the leader in proving, and then standing behind, both clinical and economic utility of testing.
read full article ›At Real Endpoints we are always excited to celebrate National Pharmacists Day to recognize the contributions to healthcare delivery our pharmacist colleagues and friends make each and every day. Thank you!
read full article ›A recent opinion piece by Sree Chaguturu, Chief Medical Officer, #cvshealth raises some interesting points about sustainable ways to INCREASE specialty drug coverage through innovative strategies. Two ideas caught our attention - combining coverage for all specialty medications (including those currently under the medical benefit), under the pharmacy benefit; and requiring value-based agreements (VBAs), where costs are aligned with clinical outcomes and effectiveness.
read full article ›Take a look at the year-end edition of Real Viewpoints, a newsletter for senior decision makers. In this edition we discussed rare and orphan disease coverage issues.
read full article ›Not surprisingly, the Abbott Report - Improving Patient Experience by Addressing Unmet Needs in Vascular Disease highlights the disparity between a patient’s actual experience and the physician / healthcare administrator’s perceptions of a patient’s experience.
read full article ›A very clever idea: a value-based agreement between drug company and, as our own Susan Raiola points out, the Medicare patient (though payer wins, too).
read full article ›An interesting piece (featuring our very own Roger Longman and Susan Raiola) on the growing focus on lung cancer drugs for value based deals.
read full article ›